Recurrent Melanoma After Progression on Anti-PD-1 Therapy
Source: Targeted Oncology, May 2019
Entinostat in combination with pembrolizumab (Keytruda) induced responses in patients with recurrent or metastatic melanoma who have progressed on or after prior anti–PD-1 therapy, according to results of a phase II trial.1
In findings from the melanoma cohort of the ENCORE-601 trial (NCT02437136) presented at the 2019 AACR Annual Meeting, the PD-1/HDAC inhibitor combination regimen demonstrated an objective response rate (ORR) of 19% (95% CI, 9%-32%) and a clinical benefit rate (CBR) of 36% (95% CI, 23%-50%) in patients with recurrent melanoma.
“In patients with progressing melanoma on prior PD-1 blockade including prior PD-1 and CTLA-4 blockade—clearly a group with limited treatment options—entinostat and pembrolizumab demonstrated significant antitumor activity,” Ryan J. Sullivan, MD, said when presenting the findings. “The combination of entinostat plus pembrolizumab was clearly safe and tolerable.”